A Phase I/IIa, Open-label, Dose-escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic and Preliminary Anti-tumor Activity of PH009-1 in Patients With EGFR Mutation Locally Advanced or Metastatic NSCLC
Latest Information Update: 01 Oct 2024
At a glance
- Drugs Antineoplastics (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Suzhou Puhe Pharmaceutical Technology
- 01 Oct 2024 New trial record